IMAGION BIOSYSTEMS LIMITED

(ASX**: IBX**)

1 July 2021

IBX Secures Additional Capital - Shareholders Exercise Options

MELBOURNE — Imagion Biosystems Limited (ASX: IBX) (the **Company** or **Imagion**) announces that it has received a total of $3,500 for the exercise of 70,000 Listed Options exercisable at 5 cents, expiring on 26 November 2021.

The exercise of these options has resulted in the issue of 70,000 fully paid ordinary shares, as outlined in the accompanying application for quotation (Appendix 2A).

The capital structure of the Company following the exercise of these options is:

Listed Securities	
Fully Paid Ordinary Shares	1,042,664,929
Listed Options (IBXOA) exercisable at 3 cents and expiring 28 April 2023	233,557,236
Listed Options (IBXO) exercisable at 5 cents and expiring 26 November 2021	78,298,302
Unlisted Securities	
FY20 Performance Rights	10,000,000
FY20 Performance Options and Directors Options (exercisable at $0.028 with expiry dates between 1 May 2026 and 1 May 2028)	8,500,000
FY20 Performance Options (exercisable at $0.14 with expiry dates between 30 November 2026 and 30 November 2028)	3,000,000
Options (exercisable at $0.028 on or before 24 June 2024)	2,150,000
Advisory Board Options (exercisable at $0.06, vesting quarterly over two years and with varying expiry dates between 22 August 2024 and 7 October 2024)	600,000
Performance Options (exercisable at $0.0909, vesting monthly over three years and with varying expiry dates between 30 September 2025 to 31 August 2028)	7,899,997
Performance Options (exercisable at $0.175, vesting monthly over three years and with varying expiry dates between 28 February 2026 to 31 January 2029)	1,000,000
Performance Options (exercisable at $0.115, vesting monthly over three years and with varying expiry dates between 30 June 2026 to 31 May 2029)	1,700,000

-ENDS

About Imagion Biosystems
Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology. Combining biotechnology and nanotechnology the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.

This Announcement has been approved by the Disclosure Committee of Imagion Biosystems Limited

For further information please visit www.imagionbiosystems.com

U.S. Media Contact:
Matthew Wygant
matthew@biotechwriting.com
+1-408-905-7630

Australian Media & Investor Relations:
Kyahn Williamson, WE Communications
We-AUImagionBiosystems@we-worldwide.com
+61-3-9866-4722